Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTSR1 | P30989 | 11/20 | 0.61 |
| ▸ | NTSR2 | O95665 | 9/20 | 0.61 |
| ▸ | NPY1R | P25929 | 3/20 | 0.59 |
| ▸ | NPY2R | P49146 | 1/20 | 0.59 |
| ▸ | NPY4R | P50391 | 1/20 | 0.59 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.59 |
| ▸ | SORT1 | Q99523 | 7/20 | 0.58 |
| ▸ | NMUR2 | Q9GZQ4 | 1/20 | 0.56 |
| ▸ | NMUR1 | Q9HB89 | 1/20 | 0.56 |
| ▸ | F2 | P00734 | 1/20 | 0.56 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29612082 | 0.97 | NPY1R (0.62) | NTSR1NTSR2NPY1RNPY2RNPY4R | |
| SCHEMBL29611528 | 0.97 | NPY1R (0.62) | NTSR1NTSR2NPY1RNPY2RNPY4R | |
| SCHEMBL29611824 | 0.97 | NPY1R (0.62) | NTSR1NTSR2NPY1RNPY2RNPY4R | |
| SCHEMBL29612137 | 0.97 | NPY1R (0.62) | NTSR1NTSR2NPY1RNPY2RNPY4R | |
| SCHEMBL29612065 | 0.97 | NPY1R (0.62) | NTSR1NTSR2NPY1RNPY2RNPY4R | |
| SCHEMBL29611524 | 0.97 | NPY1R (0.62) | NTSR1NTSR2NPY1RNPY2RNPY4R | |
| SCHEMBL29387174 | 0.97 | NPY1R (0.62) | NTSR1NTSR2NPY1RNPY2RNPY4R | |
| SCHEMBL29611985 | 0.97 | NPY1R (0.62) | NTSR1NTSR2NPY1RNPY2RNPY4R | |
| SCHEMBL20707335 | 0.97 | NPY1R (0.62) | NTSR1NTSR2NPY1RNPY2RNPY4R | |
| SCHEMBL29611692 | 0.97 | NPY1R (0.62) | NTSR1NTSR2NPY1RNPY2RNPY4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111812240-B | Separation method and application of oxytocin and three impurities | 上海上药第一生化药业有限公司 | 2022-05-24 | — | — | CN | claimed |
| CN-111912917-B | Separation method and application of oxytocin and at least ten impurities | 上海上药第一生化药业有限公司 | 2022-03-15 | — | — | CN | claimed |
| US-20260053883-A1 | OXYTOCIN COMPOSITIONS FOR TREATMENT OF VISUAL SNOW SYNDROME | MASKBEGONE LLC (US) | 2026-02-26 | — | — | US | disclosed |
| WO-2025235701-A1 | READY-TO-INFUSE OXYTOCIN COMPOSITIONS | AMNEAL PHARMACEUTICALS LLC (US) | 2025-11-13 | — | — | WO | disclosed |
| US-20250345266-A1 | READY-TO-INFUSE OXYTOCIN COMPOSITIONS | AMNEAL PHARMACEUTICALS LLC (US) | 2025-11-13 | — | — | US | disclosed |
| US-12466855-B2 | Labeled oxytocin and method of manufacture and use | TONIX PHARMA LIMITED (IE) | 2025-11-11 | — | — | US | disclosed |
| US-20250319153-A1 | MAGNESIUM-CONTAINING OXYTOCIN FORMULATIONS AND METHODS OF USE | TONIX PHARMA LTD (IE) | 2025-10-16 | — | — | US | disclosed |
| US-20250255930-A1 | METHODS OF TREATMENT OF TINNITUS USING DERIVATIVES OF OXYTOCIN | MASKBEGONE LLC (US) | 2025-08-14 | — | — | US | disclosed |
| US-20250152706-A1 | COMPOSITIONS FOR ORAL DELIVERY OF BIOTHERAPEUTICS | Intract Pharma Limited (GB) | 2025-05-15 | — | — | US | disclosed |
| WO-2025094953-A1 | ESTIMATION SYSTEM, METHOD FOR ESTIMATING MOLECULAR CONFORMATION, AND ESTIMATION PROGRAM | 中外製薬株式会社 | 2025-05-08 | — | — | WO | disclosed |
| EP-4541348-A2 | MAGNESIUM-CONTAINING OXYTOCIN FORMULATIONS AND METHODS OF USE | Tonix Pharma Limited (IE) | 2025-04-23 | — | — | EP | disclosed |
| EP-4021410-A1 | OXYTOCIN COMPOSITIONS FOR TREATMENT OF TINNITUS | New York University (US) | 2022-07-06 | — | — | EP | disclosed |
| CN-107847552-B | Magnesium-containing oxytocin formulations and methods of use | 三叉神经股份公司 | 2022-07-01 | — | — | CN | disclosed |
| CN-111812240-B | Separation method and application of oxytocin and three impurities | 上海上药第一生化药业有限公司 | 2022-05-24 | — | — | CN | disclosed |
| EP-3988170-A1 | FATTY ACIDS AND THEIR USE IN CONJUGATION TO BIOMOLECULES | Novartis AG (CH) | 2022-04-27 | — | — | EP | disclosed |
| CN-112979509-B | Trifluoromethanesulfonyl alkynamide compound and preparation method and application thereof | 江西师范大学 | 2022-04-22 | — | — | CN | disclosed |
| CN-111912917-B | Separation method and application of oxytocin and at least ten impurities | 上海上药第一生化药业有限公司 | 2022-03-15 | — | — | CN | disclosed |
| US-11266711-B2 | Oxytocin compositions and methods of use | ELGAN PHARMA LTD (IL) | 2022-03-08 | — | — | US | disclosed |
| CN-114133443-A | Fatty acids and their use in conjugation with biomolecules | 诺华股份有限公司 | 2022-03-04 | — | — | CN | disclosed |
| US-11241477-B2 | Oxytocin compositions for treatment of tinnitus | NEW YORK UNIVERSITY (US) | 2022-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250152706-A1 | COMPOSITIONS FOR ORAL DELIVERY OF BIOTHERAPEUTICS | TMPRSS15, PGA5, LNPEP | NTSR1 3023/4885NTSR2 2814/4885NPY1R 4029/4885 |
| US-20260053883-A1 | OXYTOCIN COMPOSITIONS FOR TREATMENT OF VISUAL SNOW SYNDROME | OXTR, AVPR2, AVPR1B | NTSR1 469/4885NTSR2 351/4885NPY1R 31/4885 |
| US-12466855-B2 | Labeled oxytocin and method of manufacture and use | OXTR, AVPR1A, AVPR1B | NTSR1 112/4885NTSR2 151/4885NPY1R 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.